Post-vaccination seroprotection rates (defined as HI ≥40) for the 2009 H1N1 influenza vaccine shown as percentages in all subjects (n=105)
| All subjects (n=105) | |
| All subjects | 52/105 (50%) |
| Non-immunosuppressed, based upon medication | 18/28 (64%) |
| Immunosuppressed, based upon medication | 34/77 (44%) |
| Corticosteroid monotherapy | 2/3 (67%) |
| Imod/MTX monotherapy | 11/26 (42%) |
| Biological monotherapy | 16/34 (47%) |
| Combined Imod/biological/steroid | 5/14 (36%) |
HI, haemagglutinin inhibition; Imod, immunomodulators (azathioprine or 6-mercaptopurine); MTX, methotrexate.